Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Table 4 Univariate analysis of impact of various characteristics on patient survival

Characteristics	n	DFS			P value	OS			P value
		Mean (mo)1	3-yr2	5- yr2		Mean (mo)1	3- yr2	5- yr2
Sex
Male	90	61.8 ± 25.9	81.1%	74.4%	0.803	65.5 ± 22.2	84.4%	79.9%	0.855
Female	35	65.6 ± 24.6	82.9%	76.9%		69.5 ± 20.1	88.6%	79.8%
Age (yr)
< 60	73	63.3 ± 26.3	80.1%	71.1%	0.533	68.4 ± 22.0	86.3%	80.7%	0.908
≥ 60	52	62.4 ± 24.6	82.7%	80.7%		64.2 ± 21.5	84.6%	78.7%
Tumor size (cm)
≤ 3	48	62.5 ± 26.1	81.2%	77.0%	0.571	65.0 ± 22.4	83.3%	79.2%	0.962
> 3	77	63.2 ± 25.3	81.8%	74.0%		67.7 ± 21.6	87.0%	80.3%
BMI
< 25	100	60.5 ± 26.8	77.0%	69.9%	0.024	65.3 ± 22.7	82.0%	76.9%	0.050
≥ 25	25	72.7 ± 16.6	96.0%	96.0%		72.1 ± 17.0	96.0%	92.0%
Tumor grade
1	28	64.7 ± 28.0	78.6%	75.0%	0.852	69.4 ± 22.5	85.7%	78.6%	0.931
2, 3	97	62.4 ± 25.0	82.5%	75.2%		65.6 ± 21.7	85.6%	80.2%
cTNM
II	39	69.2 ± 23.2	87.2%	84.6%	0.067	71.9 ± 18.8	92.3%	87.2%	0.137
III	86	60.0 ± 26.2	79.1%	70.7%		64.2 ± 22.8	82.6%	76.4%
CEA (ng/mL)
< 5	62	77.0 ± 4.1	69.2%	69.2%	0.789	79.6 ± 3.7	80.6%	73.9%	0.384
≥ 5	58	80.4 ± 4.3	82.8%	74.0%		86.1 ± 3.4	89.7%	84.5%
CA19-9 (U/mL)
< 35	102	81.3 ± 3.1	83.3%	75.4%	0.174	84.2 ± 2.7	86.3%	80.2%	0.597
≥ 35	18	68.1 ± 9.2	72.2%	66.7%		78.3 ± 7.8	77.8%	72.2%
CRT efficacy
Poor	74	60.7 ± 27.2	78.4%	67.5%	0.031	66.2 ± 23.2	83.8%	75.6%	0.144
Good	51	66.1 ± 23.0	90.2%	86.0%		67.3 ± 19.9	88.2%	86.1%
ypTNM
ypcr,I, II	91	66.1 ± 24.0	85.7%	82.3%	0.005	68.5 ± 20.1	89.0%	84.4%	0.041
III	34	54.3 ± 28.0	70.6%	55.6%		61.6 ± 25.5	76.5%	67.6%
Adjuvant CT
No	21	60.2 ± 31.5	71.4%	71.4%	0.385	63.5 ± 26.5	76.2%	66.3%	0.229
Yes	104	63.5 ± 24.3	83.7%	75.8%		67.3 ± 20.8	87.5%	82.7%
OME
Non- EOU	62	70.0 ± 25.8	85.5%	75.6%	0.658	73.9 ± 21.9	90.3%	82.0%	0.754
EOU	63	55.9 ± 23.5	77.8%	74.6%		59.5 ± 19.5	82.5%	77.6%
OME (200 mg)
Non-EOG	96	62.0 ± 28.2	77.1%	69.6%	0.032	66.9 ± 24.1	82.3%	76.9%	0.092
EOG	29	65.9 ± 13.3	96.6%	46.7%		65.8 ± 12.0	96.6%	89.5%

¹Mean ± SD (mo);

²Three or 5 years survival rate. EOU: Eligible OME users; Non-EOU: Non-eligible OME users; EOG: Effective OME group; Non-EOG: Non-effective OME group; BMI: Body mass index; adjuvant CT: Adjuvant chemotherapy.